Drug Monograph

Drug/Drug Class:	**Liptruzet® (ezetimibe and atorvastatin) Tablet / Antihyperlipidemic**
Prepared for:	MO HealthNet
Prepared by:	Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Liptruzet® is available in four strengths: 10mg of ezetimibe and 10mg of atorvastatin; 10mg of ezetimibe and 20mg of atorvastatin; 10mg of ezetimibe and 40mg of atorvastatin; and 10mg of ezetimibe and 80mg of atorvastatin. All doses are supplied as 10-count foil packages.
Manufacturer:	Merck & Co., Inc. Whitehouse Station, NJ 08889
Indications:	Liptruzet® is indicated as an adjunct to diet for the reduction of elevated total cholesterol and low-density lipoprotein (LDL) cholesterol in patients with primary hyperlipidemia or homozygous familial hypercholesterolemia.
Costs:	$5.50 per tablet of Liptruzet® all strengths. Wholesale Acquisition Cost
Summary of Findings:	The Division recommends this product be considered for inclusion in the state specific Preferred Drug List and is currently under solicitation.
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Non-Preferred Agent ☐ Appropriate Indications ☒ Under Solicitation

Prepared By: Chelsea Ames, Pharm.D. Candidate
Date: August 2, 2013

© 2013 Xerox Heritage, LLC All Rights Reserved.